Drug Interaction Report

If you have recently been vaccinated with SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant, you should not receive pemivibart for at least 14 days. Treatment with pemivibart may reduce the effectiveness of SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant as it could interfere with the vaccine's ability to produce an adequate immune response to the COVID-19 virus. However, you should continue to receive SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant as indicated by local guidelines based on your condition. Pemivibart should not be used as a replacement for SARS-CoV-2 (COVID-19) ChAdOx1 vaccine, recombinant. Talk to your doctor or other healthcare providers if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.